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Background/aim: To assess the efficacy and side effects of concurrent weekly chemotherapy and radiotherapy with simultaneous
integrated boost (SIB) technique for nasopharyngeal cancer (NPC).
Materials and methods: A total of 51 consecutive patients with diagnosis of NPC were treated between February 2010 and December
2015. The median dose for PTV70 (range: 60–82) was given in 33 fractions (range: 31–35). Forty-five of the patients received concomitant
weekly chemotherapy between 3–7 cycles (median 6). Eleven patients received neoadjuvant and thirty-nine patients received adjuvant
chemotherapy.
Results: At a median follow-up 43 months (range: 2–76) the estimated 5-year overall survival and disease-free survival were 74.6% and
62.6%, respectively.
Conclusion: In radiotherapy of advanced NPC, generally a considerable amount of normal head and neck tissues might have to be
irradiated in addition to gross tumor volume, involved node, and elective neck irradiation. Together with chemoradiotherapy, poor oral
hygiene and inadequate nutritional support result in excessive morbidity. Despite loco-regional success of concurrent chemoradiotherapy,
distant metastasis is still the major pattern of treatment failure in the intensity modulated radiotherapy era. We need to improve our
adjuvant chemotherapy regimens or develop new drugs.
Key words: Nasopharyngeal carcinoma, helical tomotherapy, concomitant weekly chemotherapy

1. Introduction
Nasopharyngeal cancer (NPC) arising from surface
epithelial cells of the nasopharynx was first reported
as different type of cancer by Regaud and Schmincke in
1921 (1). Compared with Asians, NPC is uncommon in
western populations; the lowest ratio with an incidence
of 0.2 to 0.5 cases per 100,000 people in the United States
and the highest ratio with 20 to 50 cases per 100.000
people in southern China (2,3). In the Turkish population,
the incidence is between these two extremes and most
of the patients are middle-aged males with a low to
median socioeconomic status. Fried meat is especially
an important risk factor for the southeastern Anatolian
region of Turkey (4). The big variations among geographic

regions and ethnic predisposition indicate the complex
nature of etiology and the interaction of genetic, viral,
environmental, and dietary risk factors (2,3). Preliminary
studies on plasma Epstein-Barr virus (EBV) DNA proved
that it can be a promising screening tool for early detection
of NPC in endemic areas of southern China. In addition,
EBV DNA can be a powerful prognosticator of recurrence
and survival as well as a strong complement for tumor
burden and staging (5,6).
Three subtypes of NPC are recognized in the World
Health Organization (WHO) classification: Type 1,
squamous cell carcinoma, typically found in the older adult
population; Type 2, nonkeratinizing carcinoma; Type 3,
undifferentiated carcinoma. Most cases in childhood and
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adolescence are Type 3, with a few Type 2 cases. Type 2 and
3 are associated with elevated Epstein-Barr virus titers but
Type 1 is not (2,3,5,6).
Upper cervical lymph adenopathy is the initial
presentation in many patients. Symptoms related to
the primary tumor include epistaxis, nasal obstruction,
and discharge. Cranial nerve palsies due to skull base
involvement lead to a variety of symptoms. Distant
metastasis, at which the bone is most affected, is seen in
3% to 6% of the cases at presentation and may occur in
18% to 50% of the cases during the disease course (2,3).
Because of the anatomic location and vicinity to
critical structures, tumor resection without excessive
morbidity is very challenging in NPC (7,8). Primary
surgical intervention of NPC was abandoned in 1950.
Treatment strategy should be tailored to 3-dimensional
conformal radiation therapy (3-DCRT) and recently
intensity modulated radiotherapy (IMRT). While singlemodality therapy is adequate for the early stages of NPC (I,
II), combined-modality therapy is necessary for advanced
stages (III, IV) (2,3). It has not yet been proved whether
induction or adjuvant chemotherapy adds further benefit
to CCRT. It remains to be investigated (2,3,9–15).
The development of IMRT has greatly eliminated the
shortcomings of traditional radiotherapy techniques (16–
21). With IMRT, not only the dose coverage and conformity
to the tumor target area improved but also the damage
to normal tissues, particularly to the salivary glands, is
reduced. IMRT significantly ameliorates xerostomia and
prevents a decrease in salivary secretions. Nevertheless,
more than 30% of IMRT-treated NPC patients still suffer
from long-term side effects. A newly developed technique,
helical tomotherapy (HT), combines inverse planning of
intensity modulation and a full 360-degree radiation beam
direction, resulting in better dosage conformity, higher
tumor control probability (TCP), and lower normal tissue
complication probability (NTCP).
2. Materials and methods
2.1. Patient characteristics
Between February 2010 and December 2015, 51 consecutive
patients with newly diagnosed NFC were treated with
image guided (IG)-IMRT. All patients including one
with distant liver and bone metastasis at presentation
were evaluated in this study. Patient characteristics are
indicated in Table 1. The pretreatment evaluation consisted
of flexible fiberoptic nasopharyngoscopy examination,
blood chemistry tests, computed tomography (CT) scans,
magnetic resonance imaging (MRI), and dental evaluation.
18-Fluoro-deoxyglucose positron emission tomography
(FDG-PET) for the purpose of radiotherapy planning and
distant metastasis evaluation was obtained in 38 of the 51
patients. The median age was 50 years (range: 9–78 years).

Table 1. Patient characteristics.
Characteristics

Number
Range: median

Sex
Female: Male
Age

10: 41
9- 78: 50

T-stage
T1: T2: T3: T4

15: 16: 6: 14

N-stage
N0: N: N2: N3
Stage
1: 2: 3: 4A: 4: 4C
Metachronous second cancers
Lung: Larynx: Bladder
Metastasis at diagnosis
Liver
Metastasis after treatment
Bone: Liver: Mediastinal
Pathology
WHO Type I: II: III
ECOG performance status
0: 1: 2
Neoadjuvant CT
Yes: No
Concomitant CT
Yes: No
Adjuvant CT
Yes: No
Symptom at presentation
Neck mass
Hearing deficits or ear discharge
Nasal obstruction or bleeding
Headache
Swallowing problems and cranial nerve palsy
Weight loss during
chemoradiotherapy
<6: ≥6

9: 14: 17: 11
3: 12: 13: 11: 11: 1
1: 1: 1
1
4: 4: 1
5: 27: 19
13: 29: 9
11: 40
45: 6
37: 14
24
14
11
6
6
20: 31

Neutropenia
Grade 0: 1: 2: 3

26: 1: 11: 1

Oral mucositis
Grade 0: 1: 2: 3

1: 11: 26: 12

Temporal lobe necrosis

1

Hearing loss
Left side: right side

3: 2

Death
Nonrelated to NFC
Treatment toxicity
Metastatic and progressive diseases

2
3
6
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Of the total 51, 41 patients were male. The distribution of
clinical stages, according to the American Joint of Cancer
Committee, was 3 patients (5.9%) at stage I, 12 (23.5%) at
stage II, 13 (25.5%) at stage III, 11 (21.6%) at stage IVA, 11
(21.6%) at stage IVB, and 1 (2%) at stage IVC. T1, T2, T3,
and T4 diseases were found in 15 (29.4%), 16 (31.4%), 6
(11.8%), and 14 (27.5%) patients, respectively. N0, N1, N2,
and N3 diseases were found in 9 (17.6%), 14 (27.5%), 17
(33.3%), and 11 (21.6%) patients, respectively. According
to the ECOG performance scale 13, 29, and 9 patients
have 0, 1, and 2 performance status, respectively. The most
frequently seen symptoms at presentation were a neck
mass in 24 (47%) patients, hearing loss or ear drainage
in 14 (27%) patients, nasal bleeding or obstruction in
11 (22%) patients, headache in 6 (12%) patients, and
swallowing problems or cranial nerve palsy in 6 (12%)
patients. According to the WHO classification, pathologic
variations of patients consist of 5 (9.8%) patients with Type
I, 27(52.9%) with Type II, and 19 (37.3%) with Type III.
2.2. Treatment: Chemotherapy
In our cohort, 11 patients received a median of 4 cycles
of neoadjuvant chemotherapy (range 1–5), 45 patients
received concomitant weekly chemotherapy with a
median of 6 cycles (range: 3–7), and 37 patients received
adjuvant chemotherapy with a median of 3 cycles (range:
1–6). Neoadjuvant chemotherapy consists of intravenous
infusion of cisplatin at 75 mg/m2 on day 1 and continuous
intravenous infusion of 5-fluorouracil (5-FU) at 800 mg/
m2 on days 1 to 5 (120 h infusion) at 28-day intervals in 5
patients or the same protocol is followed with the addition
of docetaxel at 75 mg/m2 on day 1 in 6 patients. CCRT
was given by intravenous infusion of weekly cisplatin at
40 mg/m2 in 37 patients, or intravenous infusion of weekly
carboplatin at 30 mg/m2 plus intravenous infusion of
weekly docetaxel at 30 mg/m2 in 7 patients and weekly
75 mg/m2 carboplatin in 1 patient. Drug combination of
adjuvant chemotherapy consists of cisplatin at 75 mg/m2
on days 1 and 8 and 5-FU at 600 mg/m2 on days 1 to 5, at
3-week intervals in 33 patients, carboplatin and docetaxel
in 1 patient, and carboplatin and 5-FU in 3 patients.
Cisplatin was decreased to 50 mg/m2 if the absolute
neutrophil count was 1000–1500 cells per μL, platelet
count was 50,000–75,000 per μL, or creatinine clearance
was 40–60 mL/min. Chemotherapy was stopped if the
creatinine clearance was less than 40 mL/min.
2.3. Treatment: Radiotherapy
All patients were immobilized in the supine position
using a custom-made thermoplastic cast from head to
shoulders (Klarity Medical Equipment Co.). The 3-D
volumetric scans (true point PET-CT, Biograph, Siemens)
with contrast and without contrast were acquired at 3-mm
slice thickness. The CT images were transferred to a virtual
simulation workstation (TomoCon 3.0 TetraMed) for
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registration and structure delineation. For every patient,
MRI with gadolinium contrast was obtained and registered
to the planning images. Of the 51 patients, 36 had also
PET-CT images, which were obtained in the same fixed
position with thermoplastic masks and also registered to
the planning CT image dataset for contour delineation.
The target volumes were defined by the guidance of
the ICRU 50 and 62. The primary gross tumor volume
of nasopharynx (GTVnp) and involved lymph nodes
(GTVln) were delineated out on each slice with the fusion
of MRI and PET-CT images. For patients who received
neoadjuvant chemotherapy, the prechemotherapy volume
of the nasopharyngeal extension was used for GTVnp
delineation and postchemotherapy volume of lymphatic
involvement was based on GTVln delineation. Four
clinical target volumes (CTV) were defined in our clinic;
CTV1was defined as the GTVnp plus 3–10 mm margin
and CTV2 was defined as the GTVln plus 3–7 mm margin
to encompass high risk sites of microscopic extension.
CTV3 was defined to cover the high risk subclinical
region at the primary disease site, which includes the
entire nasopharynx, anterior 1/2 to 2/3 clivus, skull base
(foremen ovale and rotundum bilaterally), parapharyngeal
space, inferior sphenoid sinus, pterygopalatine fossae,
posterior fourth to third of the nasal cavity, maxillary
sinuses, and the high risk subclinical region at the lymph
nodal regions, which include bilateral retropharyngeal,
bilateral level II, level III, and level VI lymph nodes.
CTV4 was defined as bilateral level IV lymph nodes. At
the discretion of the radiation oncologist, level IB might
also be spared or limited to the anterior border of the
submandibular gland in low risk node positive patients. We
also note that the outer most boundary of CTV2 should be
at least 15 mm from the GTVnp. The exception of that rule
was complete tumoral infiltration of clivus and tumoral
formation adjacent to the brain stem, chiasma, or optic
nerves. In those situations, the margin could be as small as
1 mm. To obtain PTVs, we enlarged CTVs 1 to 3 mm in all
directions. The spinal cord, brain stem, optic chiasm, optic
nerves, eyeballs, the lenses, temporal lobes, parotid glands,
oral mucosa, larynx, and temporomandibular joints were
delineated as the organs at risk (OAR). Treatment plans
were computed using a commercial serial tomotherapy
planning system (TomoTherapy Planning Station HiArt Version 4.2.2). IMRT was delivered with 2.5 cm field
width, pitch of 0.287, and modulation factor of 2.5. Mean
PTV for tumor was 131 cm³ (range: 27–351). Mean PTV
for involved lymph nodes was 116 cm³ (ranges 16-598).
Mean PTV 60 Gy was 511 cm³ (range: 72-887). Mean
PTV54 Gy was 149 cm³ (range: 20–345). All plans should
be normalized such that at least 95% of the volume of
the PTV70 is covered by the 70 Gy isodose surface. The
prescribed dose was 70 Gy to the PTV1, 66 Gy to the
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PTV2, 60 Gy to the PTV3, and 54 Gy to the PTV4 in 33
fractions. The calculated mean PTV doses 70 Gy, 66 Gy,
60 GY, and 54 Gy were 70.3 Gy, 66.4 Gy, 63.6 Gy, and
53.9 Gy, respectively. Simultaneous integrated boost (SIB)
technique was applied by helical tomotherapy (HT) with
one fraction daily over 5 days per week. Volumetric image
guidance by mega voltage computed tomography (MVCT)
scanning was routinely applied for every fraction of all
patients. Adaptive radiotherapy was planned in 18 patients
because of lymph node shrinkage and weight loss. The total
radiochemotherapy delivery time ranged from 42 days to
65 days (median 48 days). Radiotherapy characteristics are
given in Table 2.
All patients were evaluated weekly for treatment
response and toxicity during chemoradiotherapy.
After completion of radiotherapy, the first follow-up
was done within a month by using indirect fiberoptic
nasopharyngoscope and physical examination, thereafter
at 3-month intervals for the first year, at 4-month intervals
for the second year, and at 6-month intervals after that.
Each follow-up included a detailed questioning of early
and late side effects, clinical examination of head and
neck, complete blood, biochemical, renal and liver profile,
indirect fiber optic nasopharyngoscope examination, MR
of nasopharynx and neck, CT or ultrasound of abdomen,
chest X-ray, and, where necessary, PET-CT, bone scan,
and biopsy. Toxicity assessment was made according to
the National Cancer Institute’s Common Terminology
Criteria for Adverse Events (NCI CTCAE 3.0).
The follow-up period was measured from the first day
of adjuvant chemotherapy or chemoradiotherapy. SPSS
18 (SPSS Inc., Chicago, IL, USA) was used for statistical
analysis. The endpoints for early toxicity were death from
the neutropenia, infections, and malnutrition. The end
points for tumor control include actuarial rates of localnodal failure-free rate (LN-FFR: persistence/recurrence
in the nasopharyngeal or lymphatic region), distant
metastasis-free survival (DMFS: duration of survival
without distant metastases), and disease-free survival
(DFS: survival without distant and local failure). Diseasespecific survival (DSS: censoring deaths not due to NPC)
and overall survival (OS: duration from the beginning
date of therapy to the date of death) were measured from
any cause or the censoring of the patient at the date of last
follow-up. The actuarial rates were calculated by Kaplan–
Meier method and the differences were compared by the
log-rank test. A separate log-rank test was used to identify
the independent risk factors on survival. A 5% Type-1
error level was used to infer statistical significance.
3. Results
We assessed 51 consecutive NFC patients. No patient
was excluded from the study for any reason. Two loco-

Table 2. Radiotherapy characteristics.
Characteristics
Prescribed total dose (Gy)
Fraction dose for
PTV 70: 60: 66: 54
Mean PTV 70: Volume cm3
Mean PTV 66: Volume cm3
Mean PTV 60: Volume cm3
Mean PTV 54: Volume cm3
Number of fractions
Duration of concomitant
chemoradiotherapy (days)
Brachytherapy boost
Adaptive planning
Yes: No

Number
range: median
60–82: 70
2.17: 1.82: 2: 1.63
27–351: 131
16–598: 116
72–887: 511
20–345:149
31–35: 33
42–65: 48
1
20: 31

regional recurrences were observed during the median
(43 months) follow-up time. One patient had liver
metastases at presentation and three patients already had
metachronous second cancers (bladder, larynx, and lung).
The patient with liver metastases at diagnosis responded
to curative intent therapies. He lived more than 25 months
after metastases and there was no evidence of the locoregional relapse when he died. One patient with T1N0M0
had suspicious nasal mass appearance on MR 3 months
after completion of radiotherapy and brachytherapy boost.
He was given 70 Gy in 2.17 Gy fractions by tomotherapy,
followed with 3 Gy brachytherapy boost four times in
another institute. F-18 FDG PET-CT conducted 4.5
months after RT showed a 1 × 2 cm mass lesion, which had
an increase of uptake in the late phase (SUV(max): 9), but
2 biopsies obtained a 2-month interval by using indirect
nasopharyngoscope demonstrated granulation tissues and
the patient was in good condition with no recurrences and
no late complication five years after treatment. One patient
with distant metastasis (liver) has been given multiagent
chemotherapy.
The 5-year rate of OS, DSS, DFS, DMFS, and LNFFR are calculated as 74.6%, 78.4%, 62.6%, 74.6%, and
65.9% and are plotted in Figures 1A, 1B, 1C, 1D, and 1E,
respectively.
Sex, age, ECOG performance status, T-stage, N-stage,
stage, the presence of neutropenia, type of concomitant
chemotherapy (CCT) used, and weight loss during CRT
were examined using the log rank test (Mantel–Cox).
Among the investigated risk factors, weight loss of more
than 6 kg during CRT was found statistically significant for
DFS (P = 0.029; Figure 2). The most common acute toxicity
was oral mucositis, which caused treatment interruptions
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Figure 1A. Overall survival.

Figure 1C. Disease-free survival.

Figure 1B. Disease-specific survival.

Figure 1D. Distant metastasis-free survival.

Figure 1E. Local-nodal failure-free survival.
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Figure 2. Weight loss of less than 6 kg has a significant survival advantage on DFS. Log-rank
(Mantel–Cox) (P = 0.026).

in 13 patients in 2–15 days (median 5 days). One patient
died because of severe neutropenia during CCRT. From the
retrospective medical record examination of this patient, we
found that he had lost 30 kg (from 96 to 66 kg) in 50 days.
He had refused a nasogastric tube feeding or percutaneous
endoscopic gastrostomy tube placement during CCRT. His
concomitant chemotherapy regime consisted of weekly
cisplatin at 30 mg/m2 and weekly docetaxel at 30 mg/m2.
One patient died after the 25th day of CCRT because of
malnutrition and systemic infections. One patient died
because of toxicity during the first session of adjuvant
chemotherapy. Six patients under systemic chemotherapy
with distant metastases died due to progressive disease at
5, 14, 29, 31 46, and 56 months after completion of CCRT.
Two patients’ death was nonrelated to cancer progression;
one was 14 months later due to heart attack, and the other
was 29 months later due to intracranial hemorrhages. A
unilateral temporal lobe necrosis was developed in one
patient, after 36 months from the CCRT. She had been
operated on and histologic verification of radiation necrosis
was demonstrated. She was given anticonvulsants and
was in good condition after the operation. Grade I and II
xerostomias were observed in 26 and 17 patients, respectively.
Four patients had moderate unilateral hearing loss and one
patient had elevated thyroid stimulating hormone.

4. Discussion
After demonstration of survival benefits for CCRT
versus 2-D and 3-D conformal RT alone in a pivotal
study by Muhyi Al-Sarraf et al. (14), which was carried
out in 1998, attention among NPC investigators
turned to CCRT in the next decade. In this phase III
randomized study, they showed that 3-year survival
rate was 47% in the RT arm compared to 78% in the
CCRT arm (P = 0.001). In this era, we also witnessed
tremendous improvements in radiotherapy techniques
and extraordinary developments in radiologic and
nuclear medicine imaging. While F-18 FDG PET/
CT is giving us information about local and distant
metastases and thus correct staging, MR led us to
define correct demarcation of local tumoral invasion. In
collaboration with sophisticated IG-IMRT and modern
imaging techniques we had substantially increased locoregional control rates in this complex anatomical region.
The 5-year survival rates for NPC increased gradually
from 50% in 1960–1970s to 80% in 2000–2010s, and an
average 30% improvement obtained in this half-century
period. Local and regional failures are no longer a big
issue for NPC, but distant metastases are still the most
commonly seen failure pattern after treatment with
IMRT and concurrent chemotherapy.
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A total of 11 patients died in our cohort. Three deaths
occurred in the vicinity of concurrent chemoradiotherapy
period. These were accepted as treatment related toxicity
mortalities. It is unacceptable in terms of morbidity and
mortality. Except one, all the other mortalities occurred
in the post-CCRT period. One patient who died with
febrile neutropenia in the CCRT period had lost 30 kg of
his pretreatment weigh (from 96 to 66). He refused to get
supplementary food in the beginning of therapy and also
did not want nutritional support by nasogastric tube feeding
or percutaneous endoscopic gastrectomy tube feeding. The
febrile neutropenia remains a potentially life-threatening
complication that requires prompt medical interventions. In
our case, immediate hospitalization and rapid initiation of
broad-spectrum antibiotics therapy were not given because of
insufficient emergency care units. The other two mortalities
that occurred within 2 months after CCRT were accepted as
toxicity related deaths. One patient had severe oropharyngeal
mucositis with fungal infections and died because of sepsis;
the other had long duration filgrastim resistant neutropenia
during the first session of adjuvant chemotherapy. We
thought that aggressive CCRT and insufficient supportive
care resulted in these unacceptable mortality rates. None of
the patients who died because of treatment related toxicity
had persistence, recurrence, or loco-regional progressive
disease. We had four liver, one lung, and two bone metastases
during the follow-up period. Four metastatic patients died
because of progressive diseases under chemotherapy. One
of them had also loco-regional recurrences. In our study, T
and N stage did not have significant prognostic importance
for recurrence and loco-regional failure, probably because
of adequate coverage of irregularly shaped tumors by IMRT.
IGRT (megavoltage computed scanning for every fraction)
also adds an important contribution to the precision
and reliability of radiotherapy. In addition, aggressive
concomitant chemotherapy had an important part in this
success. However, in our cohort, 5 out of 51 nonmetastatic
NPC patients still developed distant metastases. PET-CT
images of this metastatic NPC revealed no loco-regional
recurrences. While CCRT has a significant impact on locoregional treatment of NPC, the role of adjuvant systemic
chemotherapy needs to be investigated. To fight long-term
distant metastasis of NPC, we have to improve our adjuvant
chemotherapy regimens or develop new drugs.
In a Phase III study of adjuvant chemotherapy in
advanced NPC patients, Chi et al. (11) demonstrated that
adjuvant chemotherapy had no benefit for overall survival
or relapse-free survival. In another IMRT study by Lee et
al. (18), it was demonstrated that 1 local and 1 nodal failure
but 17 systemic failures had occurred in a cohort of 67
patients. Baujat et al. (13) concluded that the overall and
event-free survival contribution of chemotherapy came from
the concomitant use, not the adjuvant one, in their analysis
of eight randomized trials, which consisted of 1753 NPC
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patients. In their matched cohort analysis, Chua et al. (12)
demonstrated that CCRT improved loco-regional control in
Chinese patients with loco-regionally advanced NPC, but
their analysis failed to detect any impact on distant failure and
survival. Sun et al. (19) published long-term results of their
IMRT series with 868 patients. They argued the role of CCRT
in patients with stage III/IVA-B disease and found that CCRT
added no survival or local control advantage in this group of
patients. Lee et al. (24) in their study assessed the therapeutic
gains and setbacks from the 2-dimensional radiotherapy to
conformal 3DRT to IMRT era. They concluded that significant
improvements in survival and reductions of serious toxicity
were obtained during this period and the average 5-year
survival rates for NPC increased steadily from around 30%
in 1960–1970, 50% in 1980, and 70% in the 1990s. This study
further showed 85% DSS in the IMRT era, with reductions of
late neurological toxicity. We had one temporal lobe necrosis,
four cases of hearing loss, and one TSH elevation and we
believe that these rates were in the acceptable limits. Despite
acute grade V toxicities, our 5-year estimated overall survival
(74.6%) and disease-specific survival (78.4%) rates are within
the proportions of the IMRT era. Because we have only
two loco-regional recurrences and our major loss is due to
acute treatment toxicities and progressive distant metastatic
disease, we conclude that loco-regional recurrences are no
longer a big issue of NFC treatment. We also did not find any
statistically significant difference among N-stage and T-stage
in Kaplan–Meier survival analyses. This is probably due to
insufficient number of patients in every group of stage in
our cohort. The compliance rate to chemotherapy was good
in our series as three, one, eight, twenty-four, and eleven
out of 45 CCRT patients completed 3, 4, 5, 6, and 7 weeks
of concomitant chemotherapy cycles, respectively. A high
level of compliance to chemotherapy and good coverage of
GTVs with high dose seem important benchmarks of locoregional success in NPC. IMRT is also capable of reducing
doses to the salivary glands, temporal lobes, cochlea, optic
apparatus, and brain stem and thus preventing sequelae
from early radiotherapy. Permanent xerostomia results in
compromised quality of life due to eating, speaking, and
swallowing problems. It also causes dental caries, infections,
ulcers, and, in worst cases, osteoradionecrosis. In our series
20 patients have adaptive planning because of weight loss and
lymph node and parotid gland shrinkage. Adaptive planning
provides an important contribution in decreasing of parotid
doses. As parotid gland dose decreases, its improvement
increases gradually in time. In our series, most grade I–II
xerostomia patients had near-complete recovery in their
salivary function at the end of one and half years. Despite
loco-regional success of IMRT, distant metastasis is the
major pattern of treatment failure in NPC.
In conclusion, more effective and less toxic treatment
modalities need to be investigated in the near future to
reduce distant metastatic failure in NPC.
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